Rare Disease - Medika Life

Although rare by definition, the collective impact of rare diseases is anything but insignificant. In the Asia-Pacific (APAC) region – home to over half of...

Real-World Evidence Unlocks Consumer Voice to Improve Care

Gil Bashe, Medika Life Editor - January 15, 2025

Patient Experience is the Key to Improving Drug Development and Health Care, but Are We Listening?

Biotech Without Borders: Reclaiming the Wonder of Science in a Distracted Age

Gil Bashe, Medika Life Editor - June 18, 2025

I was in the media bullpen with the team when the future arrived. The launch of Roferon-A, alpha interferon marked a watershed moment in medicine:...

CONNECT WITH US ON SOCIAL MEDIA

Medika Life is a unique, not-for-profit operating unit of FINN Partners and maintains an independent voice. Authors opinions may not necessarily represent those shared by FINN Partners and content cannot be promotional - rather informational centered on health issues, life science innovation, ecohealth and patient experience.

CATEGORIES

Why Healing Still Begins with Relationship

The Best Dating Game in Health Innovation Happens Just Off the Main Stage

Treating Rare Diseases: The Challenge of Access

Purpose at the Center: Craig Martin’s “Rare” Commitment to Biopharma and Patients

LATEST

TRENDING

Reevaluating Ehlers-Danlos Syndrome: How Vascular EDS Patients Are Left Behind

The Disorder That Makes Monster Faces Out of Everyone You See

HPV Urban Legends – From Contagion to Symptoms to Risks to Prevention – There Are More Rare Concerns that Deserve Our Attention

Looking for Zebras: Listening to Patients, Healing the Health System

Real-World Evidence Unlocks Consumer Voice to Improve Care

India’s Pivotal Regulatory Shift: A Possible Game-Changer in Expediting Medicines to Millions in Dire Need

Biotech Without Borders: Reclaiming the Wonder of Science in a Distracted Age

Treating Rare Diseases: The Challenge of Access

The New Covid Vaccine Is Out. Why You Might Not Want To Rush To Get It

Purpose at the Center: Craig Martin’s “Rare” Commitment to Biopharma and Patients

EDITORS CHOICE

Reevaluating Ehlers-Danlos Syndrome: How Vascular EDS Patients Are Left Behind

Treating Rare Diseases: The Challenge of Access

Real-World Evidence Unlocks Consumer Voice to Improve Care

Biotech Without Borders: Reclaiming the Wonder of Science in a Distracted Age

CONNECT WITH US ON SOCIAL MEDIA

Compliance

CORPORATE & MEDIA

Popular categories